Cellebrite DI Statistics
Total Valuation
Cellebrite DI has a market cap or net worth of $3.35 billion. The enterprise value is $2.79 billion.
| Market Cap | 3.35B |
| Enterprise Value | 2.79B |
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellebrite DI has 249.44 million shares outstanding. The number of shares has increased by 19.30% in one year.
| Current Share Class | 249.44M |
| Shares Outstanding | 249.44M |
| Shares Change (YoY) | +19.30% |
| Shares Change (QoQ) | +0.71% |
| Owned by Insiders (%) | 1.87% |
| Owned by Institutions (%) | 46.74% |
| Float | 122.90M |
Valuation Ratios
The trailing PE ratio is 43.13 and the forward PE ratio is 25.21. Cellebrite DI's PEG ratio is 1.62.
| PE Ratio | 43.13 |
| Forward PE | 25.21 |
| PS Ratio | 6.94 |
| Forward PS | 5.69 |
| PB Ratio | 6.79 |
| P/TBV Ratio | 11.65 |
| P/FCF Ratio | 20.58 |
| P/OCF Ratio | 19.02 |
| PEG Ratio | 1.62 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 35.58, with an EV/FCF ratio of 17.39.
| EV / Earnings | 35.83 |
| EV / Sales | 5.86 |
| EV / EBITDA | 35.58 |
| EV / EBIT | 41.93 |
| EV / FCF | 17.39 |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.56 |
| Quick Ratio | 1.47 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.27 |
| Debt / FCF | 0.14 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 19.10% and return on invested capital (ROIC) is 860.29%.
| Return on Equity (ROE) | 19.10% |
| Return on Assets (ROA) | 5.10% |
| Return on Invested Capital (ROIC) | 860.29% |
| Return on Capital Employed (ROCE) | 11.68% |
| Weighted Average Cost of Capital (WACC) | 11.10% |
| Revenue Per Employee | $370,175 |
| Profits Per Employee | $60,555 |
| Employee Count | 1,285 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 9.09 |
Taxes
In the past 12 months, Cellebrite DI has paid $12.35 million in taxes.
| Income Tax | 12.35M |
| Effective Tax Rate | 13.62% |
Stock Price Statistics
The stock price has decreased by -32.01% in the last 52 weeks. The beta is 1.26, so Cellebrite DI's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -32.01% |
| 50-Day Moving Average | 14.49 |
| 200-Day Moving Average | 16.26 |
| Relative Strength Index (RSI) | 39.66 |
| Average Volume (20 Days) | 1,714,960 |
Short Selling Information
The latest short interest is 4.96 million, so 1.99% of the outstanding shares have been sold short.
| Short Interest | 4.96M |
| Short Previous Month | 4.80M |
| Short % of Shares Out | 1.99% |
| Short % of Float | 4.03% |
| Short Ratio (days to cover) | 2.71 |
Income Statement
In the last 12 months, Cellebrite DI had revenue of $475.68 million and earned $77.81 million in profits. Earnings per share was $0.31.
| Revenue | 475.68M |
| Gross Profit | 400.50M |
| Operating Income | 66.48M |
| Pretax Income | 90.68M |
| Net Income | 77.81M |
| EBITDA | 78.35M |
| EBIT | 66.48M |
| Earnings Per Share (EPS) | $0.31 |
Balance Sheet
The company has $437.05 million in cash and $22.67 million in debt, with a net cash position of $512.34 million or $2.05 per share.
| Cash & Cash Equivalents | 437.05M |
| Total Debt | 22.67M |
| Net Cash | 512.34M |
| Net Cash Per Share | $2.05 |
| Equity (Book Value) | 484.32M |
| Book Value Per Share | 1.95 |
| Working Capital | 206.19M |
Cash Flow
In the last 12 months, operating cash flow was $173.54 million and capital expenditures -$13.23 million, giving a free cash flow of $160.32 million.
| Operating Cash Flow | 173.54M |
| Capital Expenditures | -13.23M |
| Depreciation & Amortization | 11.87M |
| Net Borrowing | n/a |
| Free Cash Flow | 160.32M |
| FCF Per Share | $0.64 |
Margins
Gross margin is 84.20%, with operating and profit margins of 13.98% and 16.47%.
| Gross Margin | 84.20% |
| Operating Margin | 13.98% |
| Pretax Margin | 19.06% |
| Profit Margin | 16.47% |
| EBITDA Margin | 16.47% |
| EBIT Margin | 13.98% |
| FCF Margin | 33.70% |
Dividends & Yields
Cellebrite DI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.30% |
| Shareholder Yield | -19.30% |
| Earnings Yield | 2.36% |
| FCF Yield | 4.86% |
Analyst Forecast
The average price target for Cellebrite DI is $22.50, which is 67.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.50 |
| Price Target Difference | 67.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 16.65% |
| EPS Growth Forecast (5Y) | 31.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellebrite DI has an Altman Z-Score of 6.52 and a Piotroski F-Score of 4.
| Altman Z-Score | 6.52 |
| Piotroski F-Score | 4 |